# Embleema

> Embleema is a New York- and France-based healthcare technology company that builds a unified real-world data and evidence platform for clinical research. It aggregates clinical, genomic, and patient-reported data from electronic medical records, wearables, biospecimens, and patient apps into regulatory-grade datasets, and uses no-code protocol tools plus dynamic consent to help pharmaceutical sponsors, research sites, and patient groups run non-interventional and Phase IV studies faster and at lower cost. Founded in 2017 by Robert Chu, the company started with a patient-driven health blockchain and its analytics stack has been used by the FDA for genomic regulatory review.

- **Founded:** 2017
- **Headquarters:** New York, New York, United States
- **Founders:** Robert Chu (Co-Founder & CEO), Nicolas Schmidt (Co-Founder & Chief Product Officer)
- **Team size:** 29
- **Products:** Embleema RWE Platform, PatientTruth, HIVE / regulatory bioinformatics analytics, Consent & patient engagement tools
- **Notable:** Launched the first live patient-focused healthcare blockchain network / personal health record (PatientTruth) in 2018., Closed a $3.7M Series A and joined the Techstars Alchemist Blockchain Accelerator in 2019., Analytics stack used by the FDA for genomic regulatory evaluation of health products.

## Products & services

- **Embleema RWE Platform** — An end-to-end real-world data and evidence platform that aggregates multimodal data from patient apps, study sites, EMRs, wearables, genomics, and biospecimens; features no-code drag-and-drop protocol configuration, source-tracked audit-ready data capture, and dynamic consent management for non-interventional and Phase IV studies.
- **PatientTruth** — A blockchain-based personal health record (DApp) launched in 2018 that let patients assemble their health history from dispersed records and wearables like Fitbit, control sharing via smart contracts, and participate in research.
- **HIVE / regulatory bioinformatics analytics** — A bioinformatics and regulatory analytics capability for genomic and biomarker data, associated with FDA regulatory review environments and standards work for cell and gene therapies.
- **Consent & patient engagement tools** — Dynamic consent management plus patient-facing engagement features including real-time nudges and personalized health insights, integrating 60,000+ care centers and 550+ wearable devices.

## Achievements

- Launched the first live patient-focused healthcare blockchain network / personal health record (PatientTruth) in 2018.
- Closed a $3.7M Series A and joined the Techstars Alchemist Blockchain Accelerator in 2019.
- Analytics stack used by the FDA for genomic regulatory evaluation of health products.
- Powers the Lupus Landmark Study, described as the largest lupus clinical study in the world, and the Human Epilepsy Project.
- Pharmagest acquired a ~15% strategic stake, validating the platform for pharmacy and patient applications.
- Reported ability to cut clinical research costs by roughly 40% and save clinicians ~2 hours per patient per visit.

## Latest updates

- **2019-02** — Closed $3.7M Series A led by Pharmagest and joined the Techstars Alchemist Blockchain Accelerator.
- **2019-01** — Pharmagest acquired a ~15% stake in the French-American startup.
- **2018-07** — Launched PatientTruth, the first blockchain-based personal health record, in the US.

## Links

- Website: https://embleema.com
- LinkedIn: https://www.linkedin.com/company/embleema
- Twitter/X: https://twitter.com/Embleema
- Facebook: https://facebook.com/embleema

---

Profile page: https://yespress.io/embleema
Published by YesPress — https://yespress.io
Last updated: 2026-07-21